Literature DB >> 10368691

Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.

E Izbicka1, K Davidson, R Lawrence, R Cote, J R MacDonald, D D Von Hoff.   

Abstract

MGI 114, an analog of illudin S, shows potent activity against a broad range of human tumors in vitro and in vivo, including drug resistant tumors. In this study we examined cytotoxicity of MGI 114 against human tumor cell lines (MCF7, MDA.MB.468, EJ1, J82, SCaBER, KG-1, HL60, and IMR-90) with differing expression of p53 and/or p21 (WAF1) tumor suppressor genes. Only MCF7 and IMR-90 express the wild type p53, WAF1 is present in high levels in MCF7 and SCaBER. WAF1 expression can be induced in KG-1, HL60, and IMR-90. The cells were treated with MGI 114 at 0.1, 1.0 and 10 micrograms/ml in 1 h exposure and with 0.01, 0.1 and 1.0 microgram/ml MGI 114 in a continuous exposure. Cell numbers were measured at days 2, 4, and 7. MGI 114 suppressed growth in all cell lines at day 2 after 1 h exposure at the two highest concentrations and at all concentrations in a continuous exposure. Some cells partly recovered from the inhibition by day 4. Expression of WAF1 had no apparent effect on growth suppression by MGI 114, however, cells with inducible WAF1 showed slower recovery from MGI 114 inhibition in comparison with the cells under non-permissive conditions. Overall, MGI 114 effectively inhibited growth of human cancer cells regardless of their p53 and WAF1 status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368691

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Irofulven induces replication-dependent CHK2 activation related to p53 status.

Authors:  Yutian Wang; Timothy Wiltshire; Jamie Senft; Eddie Reed; Weixin Wang
Journal:  Biochem Pharmacol       Date:  2006-10-27       Impact factor: 5.858

2.  Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.

Authors:  W J Berg; L Schwartz; R Yu; M Mazumdar; R J Motzer
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.

Authors:  A Scott Pierson; Peter Gibbs; Jon Richards; Paul Russ; S Gail Eckhardt; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

4.  Enhanced antitumor activity of irofulven in combination with antimitotic agents.

Authors:  Michael J Kelner; Trevor C McMorris; Rafael J Rojas; Nicole A Trani; Tami R Velasco; Leita A Estes; Pharnuk Suthipinijtham
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.

Authors:  Michael J Kelner; Trevor C McMorris; Rafael J Rojas; Leita A Estes; Pharnuk Suthipinijtham
Journal:  Invest New Drugs       Date:  2008-01-29       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.